Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ocular Hypertension: full-pipeline trial registry
12 of 57 indexed Ocular Hypertension trials are currently recruiting.
Corpus placement: #249 of 28,707 conditions by registered trial count.
57 US clinical trials · 12 currently recruiting · #249 of 28,707 conditions by registered trial count
Ocular Hypertension: 57 US clinical trials tracked, 12 recruiting.
Ocular Hypertension is the subject of 57 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most active sponsor is Allergan, running 9 of these trials.
Enrollment posture brief
Registry condition ocular-hypertension
OPEN 12 | RECR 21% | LATE 26 | EARLY 21 | RANK #249 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Hodgkin's Lymphoma (21% recruiting · 19 trials)
Ocular Hypertension lists 12 open slots (21% of 57 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ocular Hypertension on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ocular Hypertension is recruiting below its size-band peers.
12 of 57 indexed trials (21.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Ocular Hypertension research.
Allergan accounts for 9 of 57 trials (15.8%). 36 distinct sponsors appear on at least one study for this condition label.
-
Typical Ocular Hypertension enrolment sits around 164 participants.
Median target enrolment is 164 among the 55 trials that report a genuine target (sentinel values excluded). 20 of those (36.4%) plan for fewer than 100 participants.
-
Ocular Hypertension research is mostly interventional.
51 interventional and 6 observational studies make up this index (89.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
57 total, page 1 of 2
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
University of Alabama at Birmingham
NCT06629649
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
SpyGlass Pharma
NCT07218783
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
SpyGlass Pharma
NCT07218796
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
Amneal Pharmaceuticals
NCT06267274
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
Amneal Pharmaceuticals
NCT05401357
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
Smartlens
NCT06689696
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension
AbbVie
NCT04499248
Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension
PolyActiva Pty
NCT06964191
DSLT for Reducing Medication in Glaucoma
The Eye Institute of West Florida
NCT07390890
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
Mayo Clinic
NCT07325240
Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
59th Medical Wing
NCT05844384
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
University of Miami
NCT07217678
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction
Alcon Research
NCT07082816
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
AbbVie
NCT03891446
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
SpyGlass Pharma
NCT06120842
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
Laboratoires Thea
NCT05389267
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
Aerie Pharmaceuticals
NCT02207621
Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Aerie Pharmaceuticals
NCT02558374
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Nicox Ophthalmics
NCT04630808
Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients
Laboratoires Thea
NCT05397600
Evaluation of Safety and Efficacy of PDP-716
Sun Pharma Advanced Research Company Limited
NCT03450629
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
Allergan
NCT02247804
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
Glaukos Corporation
NCT03519386
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Allergan
NCT00332436
Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular Hypertension
Allergan
NCT00332072
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
Pfizer's Upjohn has merged with Mylan to form Viatris
NCT00277498
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension
Allergan
NCT00652106
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Bausch & Lomb Incorporated
NCT01749930
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
Novartis Pharmaceuticals
NCT00846989
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
Allergan
NCT00440011
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
Allergan
NCT04647214
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
D. Western Therapeutics Institute
NCT05913232
Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma
EyePoint Pharmaceuticals
NCT04405245
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
Bausch & Lomb Incorporated
NCT00441883
Pigment Dispersion Syndrome With and Without Glaucoma
National Eye Institute (NEI)
NCT00001152
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
Allergan
NCT01253902
Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
Allergan
NCT01110499
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
Sun Pharma Advanced Research Company Limited
NCT00945958
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
Inotek Pharmaceuticals Corporation
NCT01123785
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
Ono Pharmaceutical Co.
NCT02083289
A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension
Allergan
NCT01863953
Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).
Qlaris Bio
NCT04830397
Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma
Amakem
NCT01693315
A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension
Alcon Research
NCT00465803
Safety and IOP-Lowering Effects of WB007
Bausch & Lomb Incorporated
NCT04149899
Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma
Shire
NCT03131167
Travoprost Five Day Posology Study
Alcon Research
NCT01114893
Intraocular Pressure During Robotic Assisted Laparoscopic Procedures Utilizing Steep Trendelenburg Positioning
United States Naval Medical Center, San Diego
NCT01261871
Safety and Efficacy of a Glaucoma Drug Delivery System
Vistakon Pharmaceuticals
NCT00824720
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
Cornerstone Health Care, PA
NCT02167035
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 11 |
| Phase 3 | 21 |
| Phase 4 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Ocular Hypertension records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ocular Hypertension trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ocular Hypertension page
57 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Ocular Hypertension trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Allergan sponsors the most Ocular Hypertension trials on record, review their full trial history before evaluating a specific study. See Allergan's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ocular Hypertension condition card totals 57 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.